Chlamydia in Testicular Tissue Linked to Male Infertility
|
By LabMedica International staff writers Posted on 26 Oct 2019 |

Image: The histological detection of chlamydia in human testicular biopsies (Photo courtesy of Queensland University of Technology).
Infectious diseases, such as mumps virus infection of the human testis, are known to play a role in spermatogenic dysfunction and have been associated with abnormal sperm parameters. Bacteria including Escherichia coli, mycoplasmas and Chlamydia trachomatis in human semen are also associated with abnormal sperm parameters.
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
Latest Microbiology News
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
- RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
- Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







